Business Wire

Gilead Appoints Christi L. Shaw as Chief Executive Officer of Kite

Share

Gilead Sciences, Inc. (NASDAQ: GILD) today announced that Christi L. Shaw will join the company as Chief Executive Officer of Kite, a Gilead Company, and will become a member of Gilead’s senior leadership team.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190711005777/en/

Ms. Shaw is a renowned leader with deep experience providing commercial, financial, strategic, medical and operations leadership across the biopharmaceutical industry. Ms. Shaw currently serves as Senior Vice President of Eli Lilly &. Co., and President of Lilly Bio-Medicines. She also serves as a board member of both Avantor, Inc. and the Biotechnology Industry Organization (BIO), and as an advisor to the Healthcare Businesswomen’s Association.

Prior to joining Lilly, Ms. Shaw most recently served as U.S. Country Head and President of Novartis Corp. and North American Head of Novartis Oncology. She earned a BA in Business Administration from Iowa State University and an MBA from the University of Wisconsin.

“We conducted an extensive search for a new leader at Kite and we believe that Christi’s unique set of skills will allow us to continue to build on our leadership position in cell therapy,” said Daniel O’Day, Chairman and Chief Executive Officer of Gilead. “Christi’s vast experience across complex therapeutic areas, and particularly in oncology, will serve Kite very well. She is clearly a leader who will bring teams and individuals together and I am confident she will build upon the entrepreneurial spirit at Kite as we seek to help more people with cancer around the world.”

“Kite’s vision of transformational drug development – and of curing cancer – is one that I am extremely passionate about,” said Ms. Shaw. “I look forward to working with the many talented individuals in this organization, as we change the way cancer is treated and bring forward important, life-saving therapies.”

About Kite

Kite, a Gilead Company, is a biopharmaceutical company based in Santa Monica, California. Kite is engaged in the development of innovative cancer immunotherapies. The company is focused on chimeric antigen receptor and T cell receptor engineered cell therapies. For more information on Kite, please visit www.kitepharma.com.

About Gilead Sciences

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California. For more information on Gilead Sciences, please visit the company’s website at www.gilead.com.

For more information on Kite, please visit the company’s website at www.kitepharma.com. Learn more about Gilead at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

Contact information

Sung Lee, Investors
(650) 524-7792

Shant Salakian, Media
(424) 384-1841

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

New Research Reveals Disparity in Expectations in PSD2 Awareness Between European Retailers and Shoppers15.10.2019 23:01:00 CESTPress release

Leading eCommerce solution provider, Riskified, announced today a new European-wide study revealing a staggering disparity between retailers’ and online shoppers’ awareness of the Payment Services Directive 2 (PSD2). The survey of 2,000 consumers and 200 retailers, with respondents evenly split across the UK, Germany, France, and Spain, found that nine out of ten retailers (88%) believe consumers are ‘somewhat’ or ‘very aware’ of PSD2. However, more than three-quarters (76%) of consumers report that they haven’t even heard of it. The implementation of the regulation is set to add new security measures for all online transactions over €30. This means that for most online transactions, consumers will need to undergo multi-factor authentication to verify their identity, such as entering a code received via their mobile phone, providing biometric data such as a fingerprint, or other forms of authentication. Commenting on the findings, Eido Gal, Co-Founder and CEO, Riskified, said: “Fraud i

Dubai World Challenge for Self-Driving Transport Winners Announced for Prizes Worth USD 5.1 Million15.10.2019 20:12:00 CESTPress release

Dubai World Congress for Self-Driving Transport; organised by Roads and Transport Authority (RTA) Dubai on 15th and 16th October 2019 has attracted more than 700 technology leaders and innovators as well as 3000 visitors of the accompanying exhibition. The congress focuses on cutting-edge technologies, besides discussing and developing a general legislative structure for autonomous transport. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191015006107/en/ Winners of the Dubai World Self-Driving Transport Challenge (Photo: AETOSWire) The event is part of RTA’s efforts in support of the strategy unleashed by HH Sheikh Mohammed bin Rashid Al Maktoum, Vice-President and Prime Minister of the UAE and Ruler of Dubai, to make 25% of all trips in Dubai smart and driverless by 2030. The congress attracted 80 international experts, including five keynote speakers, who will be taking part in 40 lectures and 39 technical workshops. The

Norwegian Video Trailblazers Create Neat to Change the Game with Zoom15.10.2019 16:00:00 CESTPress release

Today at Zoomtopia 2019, Neat, a trailblazing Norwegian startup, launched its portfolio of meeting room systems designed for Zoom Video Communications, Inc. (NASDAQ: ZM). Neat's video devices are built from the ground up and developed in close partnership with Zoom. The systems are as easy to buy and set up as any consumer product, while providing complete enterprise-grade management and security. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191015005773/en/ Zoom Video Systems by Neat (Photo: Business Wire) Neat's systems embrace breakthrough technology to eliminate the complexities of video in meeting rooms, along with simplifying the entire user experience. The company has reimagined every aspect of the Zoom Rooms customer journey, including how people buy, install, use and manage its products. Based in Oslo, Norway (aka "Video Valley”), Neat has offices in the US, UK, and Taiwan. Although the company is new, Neat’s team

The success story of the Aloe Vera Drinking Gel by LR Health & Beauty continues15.10.2019 15:23:00 CESTPress release

LR Health & Beauty is further expanding its Aloe vera product portfolio with its new product Aloe Vera Drinking Gel Immune Plus. The development and manufacturing of Aloe vera products has been one of the core competences of the global direct sales company for more than 17 years. True to the motto "More quality for your life", LR now presents Immune Plus as a premium product to support the immune system. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191015005834/en/ The success story of the Aloe Vera Drinking Gel by LR Health & Beauty continues (Photo: Business Wire) The Aloe Vera Drinking Gels have been LR’s bestsellers since 2002. They offer support in different life situations and are available in various flavors. The special feature of Immune Plus is the synergetic interaction of the ingredients – 85% Aloe vera leaf gel with 8% honey, 6% ginger juice and lemon juice, enriched with vitamin C, zinc and selenium – which ha

International Experts Invited to Attend Riyadh’s Sustainable City Symposium15.10.2019 14:49:00 CESTPress release

The Royal Commission for Riyadh City (RCRC), formally known as Riyadh Development Authority, has invited international experts to participate in a Symposium setting out the next chapter in Riyadh’s development as a sustainable city, one that will enhance the lives of its citizens, while finding solutions to the difficult challenges facing all cities across the world today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191015005797/en/ International Experts Invited to Attend Riyadh’s Sustainable City Symposium (Photo: AETOSWire) ‘Riyadh’s Sustainable Future’ Symposium will take place on November 12 & 13, 2019 in Riyadh and will focus on four of the capital’s most ambitious projects, launched by King Salman bin Abdulaziz Al Saud, and stemming from an initiative from Prince Mohammed bin Salman bin Abdulaziz Al Saud, the Crown Prince. These four projects are transformative and will help to establish Riyadh as one of the most li

Mundipharma presents wealth of data for Penthrox®▼ (methoxyflurane) at EUSEM Congress, demonstrating superiority compared to standard of care in trauma pain in adults15.10.2019 14:05:00 CESTPress release

FOR EUROPEAN MEDICAL AND TRADE MEDIA ONLY Mundipharma presents new data for the inhaled analgesic Penthrox ® (methoxyflurane)6 at the European Society for Emergency Medicine (EUSEM) Congress 2019, from 12–16 October. Five abstracts are being presented, advancing the understanding of the use of methoxyflurane in the treatment of moderate to severe trauma-related pain for adults in emergency settings in Europe: MEDITA Study1 #18647: the first study to directly compare the effectiveness of methoxyflurane to standard analgesic treatment (SAT) – IV morphine for severe pain, and IV paracetamol or ketoprofen for moderate trauma pain in Italy. Methoxyflurane was superior to IV morphine (severe pain) and IV paracetamol or IV ketoprofen (moderate pain) for the primary endpoint, defined as the change in pain intensity over the first 10 minutes (overall adjusted mean treatment difference: 5.94mm; 95% CI: 8.83, 3.06mm) following pain treatment administration.1 Methoxyflurane was rated as ‘excellent